Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: a retrospective cohort study138
The Warburg effect drives dedifferentiation through epigenetic reprogramming71
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up46
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente44
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis43
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II tria40
SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation34
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment33
Cancer stem cells: a target for overcoming therapeutic resistance and relapse32
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer32
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis31
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival27
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer25
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC21
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies21
Nodal peripheral T-cell lymphomas in the new classification systems20
Effects of Helicobacter pylori eradication on the profiles of blood metabolites and their associations with the progression of gastric lesions: a20
Immune checkpoint inhibitors: breakthroughs in cancer treatment20
Advances in lung cancer screening and early detection19
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity19
Facing challenges with hope: universal immune cells for hematologic malignancies19
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study18
Improved diagnosis of thyroid cancer aided with deep learning applied to sonographic text reports: a retrospective, multi-cohort, diagnostic study17
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies17
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice16
Biological insights in non-small cell lung cancer16
Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review15
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer13
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects13
Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer13
Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity12
A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids12
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma12
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer12
Current and future trends in whole genome sequencing in cancer11
Liquid-liquid phase separation in DNA double-strand break repair11
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma11
Is adjuvant chemotherapy necessary for early gastric cancer?11
Perspective on novel proteins encoded by circular RNAs in glioblastoma11
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer10
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer9
Deep proteome profiling promotes whole proteome characterization and drug discovery for esophageal squamous cell carcinoma9
From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy9
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas9
Treatment strategies for patients with HER2-positive gastric cancer8
Research progress in tumor angiogenesis and drug resistance in breast cancer8
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi8
Comparative profiling of immune genes improves the prognoses of lower grade gliomas8
Anti-tumor pharmacology of natural products targeting mitosis8
Major roles of the circadian clock in cancer8
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer7
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer7
Metabolic regulation of immune responses to cancer7
Early detection of gastric cancer in China: progress and opportunities7
Single-arm trials for domestic oncology drug approvals in China7
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ7
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window7
The evidence and concerns about screening ultrasound for breast cancer7
Drug clinical trials on high-grade gliomas: challenges and hopes7
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer7
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation7
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer7
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy7
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification6
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer6
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects6
N6-methyladenosine (m6A) RNA modification in tumor immunity6
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer6
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation6
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer6
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer6
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB6
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy6
Decoding the complexity of metastasis6
Epigenetic regulators as the foundation for molecular classification of colorectal cancer6
Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study6
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism5
The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer5
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells5
Genomic medicine in clinical practice: national genomic medicine program in Japan5
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors5
Development of glioblastoma organoids and their applications in personalized therapy5
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine5
Global, regional, and national burden of early-onset gastric cancer5
Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting5
Targeting PP2A for cancer therapeutic modulation5
MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis5
Neoantigen cancer vaccines: a new star on the horizon5
Erratum to Treatment strategies for patients with HER2-positive gastric cancer5
0.092526197433472